Hillstar launches with $67 million autoimmune ambitions

Newly-launched Hillstar Bio, a US biotech developing precision immunology therapies for autoimmune diseases, has announced the successful closing of a $67 million Series A financing round.

The Boston-based company claims to be revolutionizing autoimmune disease treatment through a precision-driven approach that selectively depletes pathogenic cells while preserving healthy ones.

This method holds the promise of providing durable relief and improving patient outcomes compared to traditional immunosuppressive therapies, argues Hillstar, which adopts a versatile approach using tailored discovery techniques for each therapeutic, free from the constraints of traditional drug development platforms.